VOR
HEALTHCAREVor Biopharma Inc
$15.90+0.38 (+2.45%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VOR Today?
No stock-specific AI insight has been generated for VOR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.06$65.80
$15.90
Fundamentals
Market Cap$871M
P/E Ratio—
EPS$-70.50
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume627K
Avg Volume (10D)—
Shares Outstanding54.2M
VOR News
20 articles- Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeYahoo Finance·May 7, 2026
- Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?Yahoo Finance·Apr 20, 2026
- Vor Biopharma (VOR) Upgraded to Buy: Here's WhyYahoo Finance·Apr 2, 2026
- Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should KnowYahoo Finance·Apr 2, 2026
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 1, 2026
- Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 30, 2026
- Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s DiseaseYahoo Finance·Mar 30, 2026
- Vor Bio Announces $75 Million Private Placement with TCGXYahoo Finance·Mar 27, 2026
- Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 23, 2026
- Vor Bio to Participate in the 46th Annual TD Cowen Health Care ConferenceYahoo Finance·Feb 23, 2026
- Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
- Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of DirectorsYahoo Finance·Dec 23, 2025
- Vor Bio Announces $150 Million Private PlacementYahoo Finance·Dec 15, 2025
- Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?Yahoo Finance·Dec 12, 2025
- Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan CoverageYahoo Finance·Dec 10, 2025
- Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation?Yahoo Finance·Dec 2, 2025
- Vor Bio assumed with a Neutral at WedbushYahoo Finance·Nov 26, 2025
- Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Nov 25, 2025
- Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Vor Bio Announces Pricing of Public Offering of $100 Million of Common StockYahoo Finance·Nov 11, 2025
All 20 articles loaded
Price Data
Open$15.53
Previous Close$15.52
Day High$16.08
Day Low$15.49
52 Week High$65.80
52 Week Low$3.06
52-Week Range
$3.06$65.80
$15.90
Fundamentals
Market Cap$871M
P/E Ratio—
EPS$-70.50
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume627K
Avg Volume (10D)—
Shares Outstanding54.2M
About Vor Biopharma Inc
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—